findmyKOL
Clinical trialNCT00477529CompletedPhase 1/PHASE2Interventional

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

SponsorCelgeneEnrollment102Hormone Refractory Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, United States

  • Washington University School of Medicine

    St Louis, Missouri, United States

  • Nebraska Methodist Hospital

    Omaha, Nebraska, United States

  • University of Texas M.D. Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ABI-008
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Apr 2007
Primary completion
2 Jun 2011
Completion
2 Jun 2011
Last update posted
22 Nov 2019
Registered enrollment
102
Registry id
NCT00477529
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.